Vascepa gains event-reduction nod; diabetes ups ischemic risks

Friday, December 20, 2019

Vascepa approved for cardiovascular risk reduction
The FDA’s decision on cutting events in high-risk patients was based primarily on the REDUCE-IT trial.

ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
Novel oral anticoagulants may be preferred over warfarin in patients with diabetes and AFib.

HHS drug importation proposals aim to address high costs
Trump administration drops key health care proposal on day of impeachment vote.

End ‘therapeutic nihilism’ in care of older diabetic patients, says expert
‘It’s not hyperglycemia that’s killing people; it’s heart disease and renal disease.’

* * *

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgeTweets

Podcast Participants

Jim Dwyer, MD
Jim Dwyer MD, FACC, FSCAI, is a cardiologist and avid horseman in Prescott, Ariz. Trained at Saint Louis University, he spent more than 30 years in interventional cardiology. He recently hung up his lead apron and has joined a private cardiology practice. Dr. Dwyer has been producing health segments for radio broadcast for 20 years. He has no disclosures.